Table 4

Characteristics of patients developing or not developing psychiatric side effects during apomorphine infusion therapy

Patients with
psychiatric side
effects (n=11)
Patients without
psychiatric side
effects (n=14)
Age (y)66.5 (7.4)63.0 (6.8)
Duration of disease (y)4-150 17.8 (11–32)20.1 (12–20)
Duration of levodopa therapy (y)4-150 16.1 (10–25)18.5 (12–25)
Duration of “on-off” fluctuations (y)4-150 11.9 (7–24)11.7 (4–16)
Daily medication after 1–2 months of apomorphine treatment:
 Levodopa425 (0–1150) mg/day400 (0–1150) mg/day
 Apomorphine80.0 (60–151) mg/day96.5 (62–190) mg/day
Daily medication after a mean of 40.3 (9–66) months of apomorphine treatment:
 Levodopa400 (0–1250) mg/day325 (0–1950) mg/day
 Apomorphine105.0 (63–161) mg/day118 (57–174) mg/day
Part of day in “off” before apomorphine (%)54.7 (32–77)49.5 (21–74)
Part of day in “off” with apomorphine (%)26.8 (10–50)26.4 (10–50)
Number of patients having cognitive difficulties (%):
 At inclusion in study4-151 4 (36%)1 (7%)
 At final evaluation4-151 7 (64%)2 (14%)
  • Except for “age” (where mean (SD) are shown) data represent median (range).

  • 4-150 At final evaluation.

  • 4-151 As estimated from clinical examination and assessment during the 5 day pretreatment evaluation period and follow up visits (see methods).